Minor histocompatibility antigen HA-1H (HA-1H)

Minor histocompatibility antigen HA-1H is a peptide antigen derived from a functional protein, generated by a SNP that creates an immunogenic variant (KECVL**H**DDLLEA) as opposed to the non-immunogenic form (KECVL**R**DDLLEA)[1][2]. The immunogenic HA-1H peptide binds more strongly to certain MHC class I molecules (notably HLA-A*0201 and HLA-A*0206), promoting recognition by CD8+ T cells. This antigen is primarily restricted to hematopoietic cells, enabling selective targeting in leukemia or myeloma without widespread GVHD[5]. HA-1H is considered an ideal immunotherapy target in allogeneic stem cell transplantation contexts, with experimental approaches leveraging T cells, engineered TCRs, or CAR-T cells for disease eradication[4][5][6]. Monitoring HA-1H-specific T cell responses serves as a biomarker for therapeutic efficacy and relapse, while the major safety concern remains the risk of GVHD, especially if the antigen is not tissue-restricted[3][5][6].

Other names

Histocompatibility antigen 1HA-1

Stimulation of alloreactive CD8+ T cells against HA-1H peptide presented on MHC class I, leading to selective cytotoxicity of HA-1H-expressing cells Engineered receptor T cell and CAR-T cell cytotoxicity